Healio

First-line combination should be ‘new standard’ in advanced lung cancer

Please provide your email address to receive an email when new articles are posted on . Amivantamab-vmjw plus lazertinib significantly improved OS for certain patients with advanced NSCLC compared ...
Healio

Sacituzumab govitecan combo may be ‘new first-line standard of care’ in breast cancer subset

Please provide your email address to receive an email when new articles are posted on . Survival outcomes with the sacituzumab govitecan combination outweighed outcomes with chemotherapy combination ...
Seeking Alpha

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when ...
The American Journal of Managed Care

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Tislelizumab, combined with chemotherapy, is now FDA-approved for first-line treatment of unresectable or metastatic ESCC with PD-L1 expression. The phase 3 RATIONALE-306 study demonstrated ...
The American Journal of Managed Care

Understanding EGFR Mutations and First-Line Treatment

Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine. Panelists discuss how understanding EGFR mutations has transformed the ...
Medscape

First-Line Osimertinib Plus Chemo Extends Survival in NSCLC

The final overall survival (OS) results of the FLAURA2 trial support osimertinib plus chemotherapy as the new first-line standard of care for EGFR-mutated non-small cell lung cancer (NSCLC), according ...
Medscape

Osimertinib's Benefits in NSCLC Can Extend Beyond First Line

Data from the COMPEL trial support extending osimertinib (Tagrisso, AstraZeneca) therapy to patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progress on first-line treatment ...